University Hospital of North Staffordshire
Welcome,         Profile    Billing    Logout  
 7 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lambie, Mark
Elixir, NCT03994471 / 2019-004183-21: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting
3
170
Europe
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance
Iperboreal Pharma Srl, Iperboreal Pharma Srl,
End Stage Renal Disease
12/24
12/24
Person, Contact
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
Kalra, Seema
ChariotMS, NCT04695080 / 2018-005038-39: - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Recruiting
2/3
200
Europe
Cladribine (MAVENCLAD®), Placebo
Queen Mary University of London, National Institute for Health Research, United Kingdom, Merck Serono Limited, UK, Multiple Sclerosis Society of Great Britain & Northern Ireland, National Multiple Sclerosis Society, Barts & The London NHS Trust
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
12/24
12/27
Lucas, Joanne
No trials found

Download Options